OXIS International, developer of technologies and products that address oxidative stress/inflammation stemming from free radical and reactive oxygen species (ROS), today announced the international commercial launch of its proprietary joint health product, ErgoFlex™, available online.
Preventive Medicine recently published a study that demonstrated ErgoFlex's efficacy in reducing pain and increasing range of motion in people who suffer from joint pain.
The active ingredient in ErgoFlex is EGT, the only antioxidant with the ability to be delivered through the cell membrane and into the energy producing area of the cell. The antioxidant is so effective that when other powerful antioxidants are also present, the body preferentially utilizes ergothioneine. OXIS holds the exclusive patent to manufacture EGT.
OXIS' manufacturing partner, engage:BDR, has developed a comprehensive, full digital advertising campaign to support and market the pipeline of OXIS' proprietary EGT™ dietary supplements and anti-aging personal care products.
"This is a major step forward in demonstrating the company's focus of delivering our proprietary EGT-based products direct to consumers. Our partners at engage:BDR have an outstanding track record executing on direct-to-consumer product campaigns and ability to deliver our product message to a much-targeted audience that will make for a very successful launch. I am anticipating significant revenue ramp-up with ErgoFlex with additional products to follow soon," David Saloff, chairman and CEO of OXIS stated in the press release.
For more information visit oxis.com
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net